relapse site was the peritoneum in about half of the patients with stage III GC. 1, 2 Therefore, prevention of peritoneal recurrence is important to improve the prognosis of stage III GC. Peritoneal recurrence of stage III GC suggests that occult-free cancer cells already exist in the peritoneal cavity or that cancer cells are easily spread into the peritoneal cavity from the gastric wall in the intraoperative period.
To prevent peritoneal recurrence, there is a need for the development of a novel approach, such as neoadjuvant chemotherapy (NAC). NAC has the potential benefits of tumor reduction, micrometastasis eradication in the peritoneal cavity, and consequently improved prognosis. 3 Some cisplatin and S-1 (CS) regimens have been used as NAC for clinically resectable GC by the Japan Clinical Oncology Group (JCOG). The JCOG0210 phase II trial (for clinically resectable type 4 and large type 3 GC) reported a clinical response rate of 51%, a 3-year survival rate of 24.5%, and a high frequency of peritoneal recurrence (29.8%). 4 Therefore, the CS doublet regimen as NAC might be insufficient to prevent peritoneal metastasis.
Paclitaxel is an antitumor agent isolated from the bark of the yew tree (Taxus brevifolia) that acts on microtubules during mitosis, resulting in antitumor activity. Paclitaxel has a high rate of transition into the peritoneal cavity, even when administered intravenously. 5 Regimens comprising intravenous (IV) administration of paclitaxel and cisplatin plus oral administration of S-1 (PCS) have shown good efficacy, with a favorable response rate and median OS rate in patients with untreated metastatic or recurrent GC. [6] [7] [8] However, the response rate of the PCS regimen for peritoneal metastasis is reportedly only 62.5%. 6 Hence, there is still a need for other approaches that focus on the prevention of peritoneal metastasis.
A recent study reported the efficacy of intraperitoneal (IP) administration of paclitaxel in patients with GC with peritoneal metastasis and confirmed that IP-free cancer cells disappeared 24 hours after IP paclitaxel administration, even after a single administration. 9 Hence, IP chemotherapy might be favorable to prevent peritoneal metastasis. We devised a new regimen that adds the systemic triplet regimen (PCS) to IP paclitaxel and focused on the prevention of peritoneal metastasis.
We conducted the present phase II study to evaluate the feasibility and efficacy of NAC comprising a single IP administration of paclitaxel followed by IV paclitaxel and cisplatin with S-1 for clinical stage III GC.
| MATERIALS AND METHODS

| Study design and patients
The present trial was designed to evaluate the feasibility and efficacy of NAC comprising a single IP administration of paclitaxel followed by IV paclitaxel and cisplatin with S-1 for clinical stage III GC. The included patients had histologically proven and clinically resectable gastric adenocarcinoma with a target lesion, based on the Response Evaluation Criteria in Solid Tumours (RECIST) guidelines v1.1. adequate organ function, which was defined as a white blood cell count more than 3500/µL, granulocyte count more than 1500/µL, platelet count more than 100 000/µL, serum creatinine less than 1.5 mg/dL, total bilirubin less than 1.5 mg/dL, and aspartate transaminase, alanine transaminase, and alkaline phosphatase levels less than 2.5× the upper limit of normal.
The treatment schedule was a single IP administration of paclitaxel during the initial staging laparoscopy, two 21-day cycles of NAC with the PCS regimen, and then D2 gastrectomy followed by adjuvant chemotherapy with one course of weekly paclitaxel, and then S-1 for 1 year (Figure 1 ). 
| Surgery
Surgery was performed between 6 and 8 weeks after the completion of chemotherapy. Surgery consisted of total or distal gastrectomy, depending on the location of the primary tumor.
D2 lymphadenectomy was routinely performed, while splenectomy was performed only for tumor involvement at the upper onethird of the greater curvature or the nodal metastases in the splenic hilum. 12 
| Adjuvant chemotherapy
One course of weekly IV paclitaxel (80 mg/m 2 on days 1, 8, and 15, followed by 7 days of rest) was administered (beginning more than 1 week after resection), followed by S-1 (80 mg/m 2 /day for 28 days, followed by 14 days of rest) for at least 1 year. 13 
| Postoperative follow-up
Patients underwent CT scans at 4, 8, 12, 16, 20, 24, 30 , and 36 months after gastrectomy, and then annually thereafter.
| Statistical analysis
The present trial was designed to detect an absolute increase in the clinical response rate of 20% compared with a phase II trial of preoperative chemotherapy with S-1 and cisplatin for clinically resectable type 4 and large type 3 GCs (JCOG0210 trial). 4 The sample size was calculated under the assumption that the thresholdresponse rate was 50% and the expected response rate was 70%. The required number of subjects was calculated to be 18 with α = 10%
(one-sided) and 1-β = 90%. Consequently, we required 20 subjects, allowing for a dropout rate of 10%. The response rate was estimated with 80% confidence intervals (CIs) and one-sided P values that were yielded using the exact method based on binomial distribution.
OS was calculated from the date of the initial staging laparoscopy to death or to the date of the most recent follow-up. DFS was calculated from the date of the initial staging laparoscopy to recurrence or to the date of the most recent follow-up. OS and DFS were estimated using the Kaplan-Meier method, where 95% CIs were calculated using Greenwood's formula. All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary,NC).
3 | RESULTS
| Patient characteristics
Between August 2010 and October 2015, 20 patients were recruited and confirmed to be eligible. Baseline patient characteristics are 
| Safety evaluation of S-1 and adverse events of NAC
We started the present protocol at level 1 in the initial six cases.
After the end of the second cycle, there were no occurrences of grade 4 neutropenia, leucopenia, or thrombocytopenia, nor grade 3 to 4 nonhematological toxicity ( Table 2 ). All six patients completed the planned cycles. The satisfactory result of this safety evaluation enabled us to proceed to the phase II trial.
In the NAC, the incidence of AE associated with IP chemotherapy was very low; only one patient developed grade 3 hematological AE after IP chemotherapy (Table 3) . Regarding systemic chemotherapy, two patients had grade 2 creatinine evaluation, and one patient had grade 4 leukopenia and neutropenia in the first cycle; therefore, these three patients needed dose reductions of S-1, cisplatin, and paclitaxel in the second cycle. The most common grade 3 or 4 hematological toxicities were leukopenia (20%) and neutropenia (35%). Nonhematological toxicities were generally mild and manageable. Fatigue was the most common nonhematologic toxicity (Table 3 ). There were no treatment-related deaths.
| Response rate to neoadjuvant chemotherapy
The primary endpoint was the clinical response rate. 
| Surgery and postoperative complications
All patients underwent surgery between 6 and 8 weeks (median, 7 weeks) after the completion of chemotherapy. Every gastrectomy was performed via laparotomy. Peritoneal lavage cytology was negative in all 20 patients. Curative total gastrectomy was performed in 13 patients, while curative distal gastrectomy was performed in seven patients. Other surgical findings are shown in Table 4 . Four patients underwent splenectomy. Surgical complications were observed in 5 patients (25.0%), comprising wound infection in three patients, abdominal abscess in one, and pneumonia in one. All of these patients recovered with conservative treatments. There were no surgery-related deaths.
| Pathological findings
The pathological effects of the chemotherapy were grade 0 in 1 (5.0%) patient , grade 1a in six (30.0%), grade 1b in five (25.0%), grade 2 in seven (35.0%), and grade 3 in one (5.0%). The pathological response rate was 65% (13 of 20) (Table 5 ). There was no correlation between the histological type (intestinal versus diffuse) and the histological response (P = 0.62; the Mann-Whitney U test).
| Postoperative chemotherapy
Weekly IV paclitaxel and S-1 postoperative adjuvant chemotherapy were initiated in 14 of the 20 patients who underwent surgery. Two patients were given only S-1 adjuvant chemotherapy at the doctor's discretion due to postoperative complications (intra-abdominal abscess in one patient, and pneumonia in the other). The remaining four patients were unwilling to receive any postoperative adjuvant chemotherapy. There was no peritoneal recurrence. The other three patients died due to other diseases at 46, 47, and 73 months after surgery, respectively.
| DISCUSSION
The aim of the present study was to evaluate the efficacy and safety of for statistical analysis, we used a one-sided analysis. In the JCOG1002 phase II trial, the sample size was calculated in a similar manner.
14
In the CS regimen of the JCOG0210 trial, S-1 was given for the first 3 weeks of a 4-week cycle, in which the dose of S-1 was increased compared with the CS regimen of the SPIRITS trial (for unresectable or recurrent GC). 15 The 
| 61
The degree of toxicity of NAC is a critical problem because of its potential adverse effects on operative morbidity and operative mortality. In the present study, the postoperative morbidity rate was 25%, but only mild complications were observed; furthermore, there were no surgery-related deaths. A previous multicenter trial (JCOG9501) reported a complication rate following standard D2 gastrectomy without NAC of 21%. 18 It is assumed that preoperative PCS chemotherapy would not increase surgical complications; hence, our PCS regimen could be acceptable as a NAC regimen for advanced GC.
In terms of resectability, our study achieved an R0 resection rate of 100%, which was superior to that achieved in the JCOG0210 trial (73.5%) and the JCOG1002 trial (85.0%). However, a single comparison of the resection rate with that from the JCOG trials is not justified, as there were differences in the conditions of the patients. The effectiveness of the present PCS regimen was also indicated by the high pathological response rate of 65.0%; the JCOG0210 trial and the JCOG1002 trial reported pathological response rates of 48% and 50%, respectively. Hence, PCS NAC showed a better therapeutic effect than other cisplatin-based regimens. Kurokawa et al 19 reported a correlation between increased pathologic response to therapy and survival for GC. Therefore, this PCS regimen may result in a good prognosis; at the end of the study period, the 3-year OS was 90.0% and the 3-year DFS was 85.0%.
No peritoneal recurrence occurred within the follow-up period. In contrast, the JCOG0210 phase II trial reported a high frequency of peritoneal recurrence (29.8%). Hence, our new regimen might prevent peritoneal metastasis. We previously reported that preoperative IP administration of paclitaxel achieved a high concentration of the drug in the peritoneal cavity over a long period of time. 20 Based on these data, the administration of IP paclitaxel was expected to eradicate occult-free cancer cells in the peritoneal cavity. The reduction in the rate of peritoneal recurrence may be associated with the efficacy of IP paclitaxel administration.
Our new regimen achieved a positive result for patients with stage III GC; however, the current study was a single-arm phase II trial.
Further phase III study is required to conclude an affirmative result.
| CONCLUSION
We demonstrated the efficacy and safety of single IP paclitaxel administration followed by sequential IV paclitaxel and cisplatin with S-1 as NAC for resectable clinical stage III GC. This regimen seems worthy of further evaluation in phase III randomized trial.
